Mizuho Rates Neumora Therapeutics (NMRA) buy, $4 Price Target

Mizuho Sticks With Buy Rating for Neumora

On June 18, 2026, Mizuho analyst Graig Suvannavejh reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA), maintaining a price target of $4.00. The call comes as the clinical-stage biopharmaceutical company continues to advance its pipeline of brain disease treatments. The $4.00 target suggests significant potential growth from the current trading price, as the firm remains optimistic about the company's long-term prospects in the neuropsychiatric space.

This rating follows a period of focus on the company's research and development efforts. Neumora is currently working through several clinical trials, which are the primary drivers for its valuation. Because the company is still in its clinical stages and does not yet have a product on the market, it isn't profitable and doesn't have a meaningful price-to-earnings ratio. Its current market cap stands at approximately $130.02 million.

Neumora Stock Trends and Performance

On Thursday, Neumora shares were trading at $1.61. This price point is roughly in the middle of its 52-week range, which spans from a low of $0.68 to a high of $3.65. While the stock has seen some recovery from its lows, it is still trading below its 200-day moving average of $1.99, though it has recently been hovering above its 50-day moving average of $1.44.

The stock's volatility is reflected in its beta of 2.74, suggesting it moves much more sharply than the broader market. Investors often see this kind of price action in the biotechnology sector, where clinical trial news can cause rapid shifts in sentiment. The company maintains a healthy liquidity position for its current operations, with a current ratio of 4.50.

Analysts Set New Price Targets

Mizuho isn't the only firm watching Neumora closely. On July 13, 2026, RBC Capital maintained an Outperform rating on the stock, though it lowered its price target from $7.00 to $5.00. Despite that reduction, the firm's outlook remains positive compared to the current share price.

Across the seven analysts who follow Neumora, the consensus is a Buy recommendation. The average price target among this group is $6.14, which is notably higher than Mizuho's $4.00 target. Individual targets vary widely, with a high estimate of $14.00 and a low of $3.00, showing a range of opinions on how the company's clinical trials will ultimately perform.

Developing Treatments for Brain Health

Neumora Therapeutics is a Watertown, Massachusetts-based company focused on finding new ways to treat brain diseases and neuropsychiatric disorders. Their lead candidate, navacaprant, is currently in phase 3 trials for major depressive disorder. They are also working on treatments for Alzheimer’s-related agitation, schizophrenia, and Parkinson’s disease. As a clinical-stage firm, its success depends almost entirely on the results of these scientific studies.

Investors will be looking toward the company's next earnings report, expected on November 5, 2026. While earnings per share was recently reported at -$1.23, the focus for biotech investors usually remains on the cash burn rate and the progress of the drug pipeline. Future updates on the phase 3 trials for navacaprant will likely be the next major catalyst for the stock.